Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system
American Journal of Preventive Cardiology · 2025-06 · 22 · 100966
DOI: 10.1016/j.ajpc.2025.100966 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2025-06. Verfasst von Demetria M Bolden und 9 weiteren Autor:innen. Beteiligte Einrichtung: Denver-Seattle Center of Innovation for Veteran Centered and Value Driven Care, Aurora, CO, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BLRD VA, CSRD VA.
Abstract (Originalsprache)
Importance: Adoption of novel therapeutics often lags for Black versus non-Hispanic White patients. Seminal clinical trials established the cardiovascular efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease. However, it is uncertain whether race influences the evidence-based prescription of these agents.
Objective
To determine whether evidence-based prescription of SGLT2i or GLP-1RA differs by Black versus White race in the Veterans Affairs (VA) healthcare system.
Design
Setting and Participants: Retrospective cohort study of US Veterans with T2D and angiographically confirmed coronary artery disease (CAD) at 84 VA medical centers over the period 2015-2023. Data from the VA Clinical Assessment, Reporting, and Tracking Program were used to construct cohorts eligible for SGLT2i or GLP-1RA treatment based on eligibility criteria for the seminal Empagliflozin, Cardiovascular Outcomes, and Mortality in T2D (EMPA-REG OUTCOME) or the Liraglutide Effect and Action in Diabetes (LEADER) trial, respectively. Multivariable logistic regression estimated adjusted odds of trial-concordant SGLT2i or GLP-1RA prescription by race. Exposures: Self-identified race. Main Outcomes and Measures: SGLT2i or GLP-1RA prescription among those with an evidence-based (trial-concordant) indication.
Results
Of 63,561 Veterans with T2D and CAD, 3527 Black and 18,668 White patients met criteria for trial-concordant SGLT2i treatment and 2020 Black and 10,103 White patients for GLP1-RA treatment. Trial-concordant prescription of both classes increased over time for both races but reached only 42 % for SGLT2i and 15 % for GLP1-RA in 2023. Black versus White race was not associated with evidence-based SGLT2i prescription (adjusted odds ratio [OR] 0.96, 95 % CI 0.89-1.04, P = 0.32). However, Black Veterans were less likely than White to be provided with a trial-concordant GLP1-RA prescription (adjusted OR 0.85, 95 % CI 0.74-0.98, P = 0.025). Conclusions and Relevance: Among patients with T2D and CAD in the VA healthcare system, evidence-based SGLT2i and GLP1-RA prescription increased over time, but many eligible patients remained untreated. Although SGLT2i prescription did not differ by race, Black versus White Veterans were less likely to receive evidence-based GLP1-RA prescription. Racial disparities in evidence-based cardiovascular drug prescription exist even in a healthcare system with few economic barriers and may be drug class-specific.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Denver-Seattle Center of Innovation for Veteran Centered and Value Driven Care, Aurora, CO, USA.
- Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Cardiology Section, Rocky Mountain Regional VA Medical Center, Aurora, CO, USA.
- School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Section of Academic Primary Care, Rocky Mountain Regional VA Medical Center, Aurora, CO, USA.
- Endocrinology Section, Rocky Mountain Regional VA Medical Center, Aurora, CO, USA.
Förderung
- BLRD VA
- CSRD VA
Zitieren
APA
Bolden, D. M., Richardson, V., Salahuddin, T., Henderson, K., Hess, P. L., Raghavan, S., Saxon, D. R., Ho, P. M., Waldo, S. W., & Schwartz, G. G. (2025). Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system. American Journal of Preventive Cardiology, 22, 100966. https://doi.org/10.1016/j.ajpc.2025.100966
Vancouver
Bolden DM, Richardson V, Salahuddin T, Henderson K, Hess PL, Raghavan S, et al. Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system. American Journal of Preventive Cardiology. 2025;22:100966. doi:10.1016/j.ajpc.2025.100966
BibTeX
@article{Bolden2025,
author = {Bolden, Demetria M and Richardson, Vanessa and Salahuddin, Taufiq and Henderson, Kamal and Hess, Paul L and Raghavan, Sridharan and Saxon, David R and Ho, P Michael and Waldo, Stephen W and Schwartz, Gregory G},
title = {Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system},
journal = {American Journal of Preventive Cardiology},
year = {2025},
volume = {22},
pages = {100966},
doi = {10.1016/j.ajpc.2025.100966}
}
EUVIMED